Table 1.
Overview of data sources and their population characteristics per country
| Study site | Name of existing study/database | Cohort+period of data collection | Oncological diagnosis | Therapy |
| France | ||||
| Hospices Civils de Lyon | Immucare Elderly | Historical (2007–2020) | Any solid tumour | ICIs |
| Hospices Civils de Lyon | Immucare BASE | Historical (2019 onward) Prospective (2021 onward) |
Any solid tumour | ICIs |
| Hospices Civils de Lyon | QoLD CART | Historical (2021 onward) | Lymphoma | CAR T cells |
| Hospices Civils de Lyon | QUALITOP CART | Prospective (2022 onward) | Lymphoma | CAR T cells |
| The Netherlands | ||||
| University Medical Center Groningen | OncoLifeS | Historical (2015 onward) Prospective (2021 onward) |
Lung cancer | ICIs |
| Nationwide CAR-T cohort | Follow that CAR | Historical (2020–2021) Prospective (2021 onward) |
Lymphoma | CAR T cells |
| Nationwide Cancer Registry (IKNL) | eQuiPe | Historical (2016–2020) | Any malignancy | Any treatment |
| Portugal | ||||
| Instituto Português de Oncologia, Lisboa | QUALITOP Lymphoma | Prospective (2021 onward) | Lymphoma | CAR T cells, ICIs |
| Spain | ||||
| Hospital Clinic de Barcelona (IDIBAPS) | Xarxa Melanoma | Historical (2020–2021) Prospective (2021 onward) |
Melanoma | ICIs |
CAR, chimeric antigen receptor; CAR T cells, chimeric antigen receptor T cells; ICIs, immune checkpoint inhibitors; QUALITOP, monitoring multidimensional aspects of QUAlity of Life after cancer ImmunoTherapy, an Open smart digital Platform for personalised prevention and patient management.